{"preliminary_commentary":{"by_channel":{"x_thread":37,"youtube":5,"podcast":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04858529\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-01T03:47:03.385Z","note":"Automated from the 39 newest of 47 indexed sources (May 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":39,"text":"- Whether carboplatin can be omitted routinely or should be reserved for selected patients\n- Whether carboplatin omission affects event-free or recurrence outcomes\n- How far neoadjuvant chemotherapy can be de-escalated, including treatment duration"},"drugs_tested":[["THP"]],"indication":"HER2-positive breast cancer","name":"neoCARHP","nct_id":"NCT04858529","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neocarhp-nct04858529. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"THP","type":"EXPERIMENTAL"},{"description":null,"label":"TCHP","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-04-30","type":"ESTIMATED"},"conditions":["Neoadjuvant Therapies for HER2+ Breast Cancer"],"enrollment":{"count":774,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)","otherNames":[],"type":"DRUG"},{"name":"investigator-selected taxane/trastuzumab/pertuzumab (THP)","otherNames":[],"type":"DRUG"}],"last_update":"2023-11-07","lead_sponsor":"Guangdong Provincial People's Hospital","official_title":"Neoadjuvant TCHP Versus THP in Patients With Human Epidermal Growth Factor Receptor 2-positive Breast Cancer (neoCARHP) : a Randomized, Open-label, Multicenter, Phase III Trial","overall_status":"UNKNOWN","phases":["PHASE3"],"primary_completion_date":{"date":"2024-04-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"pathological complete response(ypT0/is,ypN0, pCR)","timeFrame":"18 weeks"}],"references":[{"citation":"Gao HF, Ye GL, Lin Y, Huang Q, Dong J, Cao Y, Zhao YX, Chen QJ, Ma SH, Ouyang J, Ye JH, Yang HW, Zhang YQ, Zhang YC, Zhang GL, Li W, Zhang Y, Wu ZY, Lin YY, Zhu T, Zhang LL, Yang CQ, Yang M, Peng H, Chen B, Chen YT, Ji F, Cheng MY, Li JQ, Jiang Z, Wang K. Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. J Clin Oncol. 2026 Jun 10;44(17):1587-1596. doi: 10.1200/JCO-25-02176. Epub 2026 Jan 23.","pmid":"41576297","type":"DERIVED"},{"citation":"Zhu T, Huang YH, Li W, Wu CG, Zhang YM, Zheng XX, Zhang TF, Lin YY, Liu ZY, Ye GL, Lin Y, Wu ZY, Wang K. A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial. Br J Cancer. 2024 Sep;131(4):692-701. doi: 10.1038/s41416-024-02726-3. Epub 2024 Jun 25.","pmid":"38918556","type":"DERIVED"}],"start_date":{"date":"2021-04-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)","url":"https://clinicaltrials.gov/study/NCT04858529"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neocarhp-nct04858529"}